Dengue vaccine

Dengue vaccine
Vaccine description
TargetDengue fever
Vaccine typeAttenuated
Clinical data
Trade namesDengvaxia, Qdenga
Other namesCYD-TDV
AHFS/Drugs.comMonograph
License data
Routes of
administration		Subcutaneous
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)[1][2][3]
  • BR: Approved[4]
  • UK: POM (Prescription only)[5]
  • US: Rx-only (Dengvaxia)[6]
  • EU: Rx-only[7][8]
  • In general: ℞ (Prescription only)
Identifiers
CAS Number
DrugBank
ChemSpider
  • none

Dengue vaccine is a vaccine used to prevent dengue fever in humans.[9] Development of dengue vaccines began in the 1920s, but was hindered by the need to create immunity against all four dengue serotypes.[10] As of 2023, there are two commercially available vaccines, sold under the brand names Dengvaxia and Qdenga.[11][12]

Dengvaxia is only recommended in those who have previously had dengue fever or populations in which most people have been previously infected due to phenomenon known as antibody-dependent enhancement.[13] The value of Dengvaxia is limited by the fact that it may increase the risk of severe dengue in those who have not previously been infected.[14][13] In 2017, more than 733,000 children and more than 50,000 adult volunteers were vaccinated with Dengvaxia regardless of serostatus, which led to a controversy.[15] Qdenga is designated for people not previously infected.[16]

There are other vaccine candidates in development including live attenuated, inactivated, DNA and subunit vaccines.[10]

  1. ^ "Dengvaxia dengue tetravalent vaccine (live, attenuated), powder and diluent for suspension for injection (275964)". Therapeutic Goods Administration (TGA). 26 May 2022. Retrieved 9 April 2023.
  2. ^ "Prescription medicines: registration of new chemical entities in Australia, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 9 April 2023.
  3. ^ "Prescription medicines and biologicals: TGA annual summary 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 31 March 2024.
  4. ^ "Vacina contra a dengue: aplicação começa nesta semana em clínicas particulares" [Dengue vaccine: administration starts this week in private clinics]. CNN Brazil (in Portuguese). 26 June 2023. Retrieved 29 June 2023.
  5. ^ "Qdenga powder and solvent for solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC)". (emc). 22 March 2023. Retrieved 9 April 2023.
  6. ^ Cite error: The named reference Dengvaxia FDA label was invoked but never defined (see the help page).
  7. ^ Cite error: The named reference Dengvaxia EPAR was invoked but never defined (see the help page).
  8. ^ Cite error: The named reference Qdenga EPAR was invoked but never defined (see the help page).
  9. ^ Cite error: The named reference AHFS2019 was invoked but never defined (see the help page).
  10. ^ a b McArthur MA, Sztein MB, Edelman R (August 2013). "Dengue vaccines: recent developments, ongoing challenges and current candidates". Expert Review of Vaccines. 12 (8): 933–953. doi:10.1586/14760584.2013.815412. PMC 3773977. PMID 23984962.
  11. ^ World Health Organization (24 November 2023). "Meeting of the Strategic Advisory Group of Experts on Immunization, September 2023: conclusions and recommendations". Weekly Epidemiological Record. 98 (47): 599–620. hdl:10665/374327.
  12. ^ Freedman DO (November 2023). "A new dengue vaccine (TAK-003) now WHO recommended in endemic areas; what about travellers?". J Travel Med. 30 (7): 1–3. doi:10.1093/jtm/taad132. PMID 37847608.
  13. ^ a b World Health Organization (September 2018). "Dengue vaccine: WHO position paper – September 2018". Weekly Epidemiological Record. 93 (36): 457–76. hdl:10665/274316.
  14. ^ Redoni M, Yacoub S, Rivino L, Giacobbe DR, Luzzati R, Di Bella S (July 2020). "Dengue: Status of current and under-development vaccines". Reviews in Medical Virology. 30 (4): e2101. doi:10.1002/rmv.2101. hdl:1983/6d38d9b6-8e1b-4a84-85e3-edab4fc41957. PMID 32101634. S2CID 211536962.
  15. ^ Lopez V (4 December 2017). "DOJ orders NBI to investigate P3.5-B dengue vaccine scandal". STAT. Retrieved 14 December 2017.
  16. ^ "Takeda Begins Regulatory Submissions for Dengue Vaccine Candidate in EU and Dengue-Endemic Countries" (Press release). Takeda Pharmaceutical Company Limited. 25 March 2021. Retrieved 28 March 2021.